Drug Discovery 2022: driving the next life science revolution

bit.bio

bit.bio
Where: E6/E13
bit.bio combines the concepts of cellular reprogramming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines

This is possible with our precision cellular reprogramming technology, opti-ox™ - a core component of our Cell Identity Coding Platform. opti-ox is a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.

Under our ioCells brand we already have a wide range of wild type and disease model cells available for research and drug discovery including nerve cells, immune cells and muscle cells. Our portfolio is expanding at pace and all our cells are powered by opti-ox so are consistent, easy to use and highly defined.

We are currently building a clinical pipeline of cell therapies. Our areas of development are liver, immune and metabolic.
Tel: 01223 787 297
Address: The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge
Website: https://bit.bio/
Email: info@bit.bio

Staff Attending

Nicoll
Miss Roisin Nicoll
Senior Account Manager
bit.bio
View Profile